NGM Biopharmaceuticals, Inc. (NGM): Price and Financial Metrics
GET POWR RATINGS... FREE!
NGM Stock Price Chart Interactive Chart >
NGM Price/Volume Stats
| Current price | $5.09 | 52-week high | $18.25 |
| Prev. close | $5.18 | 52-week low | $2.92 |
| Day low | $5.05 | Volume | 174,968 |
| Day high | $5.28 | Avg. volume | 346,422 |
| 50-day MA | $5.16 | Dividend yield | N/A |
| 200-day MA | $10.99 | Market Cap | 415.99M |
NGM Biopharmaceuticals, Inc. (NGM) Company Bio
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.
Latest NGM News From Around the Web
Below are the latest news stories about NGM BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate NGM as an investment opportunity.
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Siobhan Nolan Mangini, President and Chief Financial Officer, will participate in the B. Riley Securities 3rd Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-o |
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key PrioritiesNGM Bio’s three-pronged corporate strategy includes the following components: Focus internal clinical development efforts on solid tumor oncology portfolioGenerate next-generation biologics through prolific in-house discovery engineSeek partners for other NGM-discovered programs including aldafermin, NGM621 and NGM936 2023 key priority to advance signal-seeking trials of myeloid checkpoint inhibitor immuno-oncology programs NGM707, NGM831 and NGM438 SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GL |
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM BiopharmMerck & Co Inc (NYSE: MRK) has notified NGM Biopharmaceuticals Inc (NASDAQ: NGM) that it will not exercise its option to license NGM621 and its related compounds. Merck will also not exercise the related ophthalmology bundle option. NGM estimated in its latest quarterly report that it could also have received $20.7 million in reimbursable expenses if Merck went ahead with NGM621. In June 2021, NGM Biopharma and Merck extended their ongoing collaboration through March 2024 with a narrower scope. |
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting--NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells while inducing minimal cytokine release in preclinical in vivo and in vitro studies-- --Immunoglobulin-like transcript 3 (ILT3) is a highly specific marker of acute myeloid leukemia (AML) with monocytic differentiation and is not expressed on non-monocytic blood cells or hematopoietic progenitor cells, making ILT3 a potentially promising target for mon |
NGM Price Returns
| 1-mo | 12.61% |
| 3-mo | -9.27% |
| 6-mo | -64.85% |
| 1-year | -66.95% |
| 3-year | -71.31% |
| 5-year | N/A |
| YTD | 1.39% |
| 2022 | -71.65% |
| 2021 | -41.54% |
| 2020 | 63.85% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...